P53 and Survival Rate in Penile Cancer
DOI:
https://doi.org/10.3889/oamjms.2019.219Keywords:
P53 expression, Survival rate, Penile cancer, Gene overexpression, MortalityAbstract
BACKGROUND: Penile cancer accounts for 0.4-0.6% of all malignancy in men in Europe and the United States of America. It also accounts for 10% of all malignancy in men in some Asian, South American, and African countries. P53 protein has the function to regulate apoptosis in the cell cycle. Therefore, the presence of p53 in cells may indicate higher proliferative activity of the cells as a feedback mechanism, indicating disease progression.
AIM: This study aims to identify the association between p53 expression and survival rate in penile cancer patients.
METHODS: This study was a retrospective observational analytic study. This study was conducted in Pathology Anatomy Laboratory Faculty of the Medicine University of Sumatera Utara/Haji Adam Malik Hospital/University of Sumatera Utara Hospital to assess p53 expression. This study was conducted from January 2018 to December 2018.
RESULTS: The total subjects in this study were 33 with the mean age of 50.79 ± 10.62. Based on clinical stage, patients in this study are divided into 11 patients (33.3%) in stage T II and 22 patients (66.7%) in stage T III/T IV. P53 expression was positive in 13 patients (35.3%). There were 19 patients (57.6) alive and 14 patients (42.4%) deceased. Statistical analysis using chi-square showed that there was an association between p53 expression and mortality (p = 0.011). In the Kaplan-Meier Curve for 3-year overall survival based on p53 expression, the survival rate in 36 months in the p53 positive group is 18%, while in p53 negative group, the survival rate was 60%. The survival rate based on p53 status was significantly different (p = 0.025).
CONCLUSION: There is a significant association between p53 expression and mortality in penile cancer patients. In conclusion, p53 expression in penile cancer cells examined by immunohistochemistry may show prognostic values in the disease progression.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Pettaway CA, Lance RS, Davis JW. Tumors of the penis. In Campbell-WalshUrology, 2012:901-1000.
Tranggono U, Umbas R. Karakteristik dan terapi penderita keganasan penis di RS Cipto Mangunkusumo dan RS Kanker Dharmais. Indonesian Journal of Cancer. 2008:45-50.
Kusmawan E, Bowolaksono, Widiana R. The Clinical Features of Penile Cancer Patients at Sanglah General Hospital Bali-Indonesia. Bali Medical Journal. 2012; 1(1):1-5.
Hakenberg OW, Protzel C. Chemotherapy in penile cancer. Therapeutic Advances in Urology. 2012; 4(3):133-8. https://doi.org/10.1177/1756287212441235 PMid:22654965 PMCid:PMC3361747
Irawan W, Warli SM. Karakteristik Penderita Kanker Penis di RSUP H Adam Malik Medan, 2015.
Reed SI. Cellcycle in Cancer Principles & Practice of Oncology 7th Ed. Editor: DeVitaJr V, Hellman S, Rosenberg S A. Lippincott & Wilkins, Philadelphia, 2005; 1: 89-94.
Zargar-Shostari K, Spiess P E, Berglund A E et al. Clinical Significanceof p53 and p16ink4 Status in a Contemporary North American Penile Carcinoma Cohort. Clinicalgenitourinary cancer. 2016; (12):1-6.
Gunia S, Kakies C, Erbersdobler A, Hakenberg O W, Koch S, May M. Expressionof p53, p21 andcyclin D1 in penile cancer: p53 predictspoor prognosis. JounalofClinicalPathology. 2012; 65:232-236.
Levi JE, Rahal P, Sarkis ÃS, Villa LL. Human papillomavirus DNA and p53 status in penile carcinomas. International journal of cancer. 1998; 76(6):779. https://doi.org/10.1002/(SICI)1097-0215(19980610)76:6<779::AID-IJC1>3.0.CO;2-V
Lam KY, Chan AC, Chan KW, Leung ML, Srivastava G. Expression of p53 and its relationship with human papillomavirus in penile carcinomas. European Journal of Surgical Oncology (EJSO). 1995; 21(6):613-6. https://doi.org/10.1016/S0748-7983(95)95262-4
Cordon-Cardo C, Zhang ZF, Dalbagni G, Drobnjak M, Charytonowicz E, Hu SX, Xu HJ, Reuter VE, Benedict WF. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer research. 1997; 57(7):1217. PMid:9102201
Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier AM, Soussi T, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol. 2000; 18(7):1465-73. https://doi.org/10.1200/JCO.2000.18.7.1465 PMid:10735894
Maeda K, Kang SM, Onoda N, Ogawa M, Sawada T, Nakata B, et al. Expression of p53 and vascular endothelial growth factor associated with tumor angiogenesis and prognosis in gastric cancer. Oncology. 2008; 55:594. https://doi.org/10.1159/000011918 PMid:9778629
Unal OF, Ayhan A, Hosal AS. Prognostic value of p53 expression and histopathological parameters in squamous cell carcinoma of oral tongue. J Laryngol Otol. 2009; 113:446.
Lopes A, Bezerra AR, Pinto CA, Serrano SV et al. p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. AUA. 2002; 168:81-6.
Marinescu A, Stepan AE, Mărgăritescu C et al. P53, p16 and Ki67 immunoexpression in cutaneous squamous cell carcinoma and its precursor lesions. Rom J Morphol Embryol. 2016; 57(2):691-6. PMid:27833960
Zargar-Shoshtari K, Spiess PE, Berglund AE, Sharma P, Powsang JM, Giuliano A, Magliocco AM, Dhillon J. Clinical significance of p53 and p16ink4a status in a contemporary North American Penile Carcinoma Cohort. Clinical genitourinary cancer. 2016; 14(4):346-51. https://doi.org/10.1016/j.clgc.2015.12.019 PMid:26794389
Ficarra V, D'Amico A, Cavalleri S, Zanon G, Mofferdin A, Schiavone D et al. Surgical treatment of penile carcinoma: our experience from 1976 to 2007. Urol Int. 2009; 62:234. https://doi.org/10.1159/000030404 PMid:10567891
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Fauriski Febrian Prapiska, Syah Mirsya Warli
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
